Beth A Overmoyer (Beth Overmoyer)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Topics

Peritoneal Dialysis

Top Venues

Nature communications

NPJ breast cancer

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Jorge Gomez Tejeda Zanudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa M Pereslete, Daniel L Abravanel, Arlindo R Ferreira, Eileen Wrabel, Karla Helvie, Melissa E Hughes, Ann H Partridge, Beth A Overmoyer, Nancy U Lin, Nabihah Tayob, Sara M Tolaney, Nikhil Wagle
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature communications 15 (1) (2024)
Jorge Gomez Tejeda Zanudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa M Pereslete, Daniel L Abravanel, Arlindo R Ferreira, Eileen Wrabel, Karla Helvie, Melissa E Hughes, Ann H Partridge, Beth A Overmoyer, Nancy U Lin, Nabihah Tayob, Sara M Tolaney, Nikhil Wagle
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature communications 15 (1) (2024)
Jorge Gomez Tejeda Zanudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa M Pereslete, Daniel L Abravanel, Arlindo R Ferreira, Eileen Wrabel, Karla Helvie, Melissa E Hughes, Ann H Partridge, Beth A Overmoyer, Nancy U Lin, Nabihah Tayob, Sara M Tolaney, Nikhil Wagle
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature communications 15 (1) (2024)
Jorge Gomez Tejeda Zanudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa M Pereslete, Daniel L Abravanel, Arlindo R Ferreira, Eileen Wrabel, Karla Helvie, Melissa E Hughes, Ann H Partridge, Beth A Overmoyer, Nancy U Lin, Nabihah Tayob, Sara M Tolaney, Nikhil Wagle
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature communications 15 (1) (2024)
Ana Christina Garrido-Castro, Meredith M Regan, Samuel M Niman, Faina Nakhlis, Claire Remolano, Jennifer M Rosenbluth, Caroline Block, Laura E G Warren, Jennifer R Bellon, Eren Yeh, Beth T Harrison, Elizabeth Troll, Nancy U Lin, Sara M Tolaney, Beth A Overmoyer, Filipa C Lynce
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. NPJ breast cancer 9 (1) (2023)
Priscilla Kaliopi Brastianos, Albert E Kim, Anita Giobbie-Hurder, Eudocia Q Lee, Nancy U Lin, Beth A Overmoyer, Patrick Y Wen, Lakshmi Nayak, Justine V Cohen, Jorg Dietrich, April Eichler, Rebecca S Heist, Ian Krop, Donald Lawrence, Jennifer Ligibel, Sara M Tolaney, Erica L Mayer, Eric Winer, Brittany Bent, Magali A de Sauvage, Nazanin Ijad, Juliana M Larson, Braxton Marion, Sally Nason, Naina Murthy, Sherry Ratcliff, Elizabeth J Summers, Maura Mahar, Helen A Shih, Kevin Oh, Daniel P Cahill, Elizabeth R Gerstner, Ryan J Sullivan
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. Nature medicine (2023)
Laura E Stevens, Guillermo Peluffo, Xintao Qiu, Daniel Temko, Anne Fassl, Zheqi Li, Anne Trinh, Marco Seehawer, Bojana Jovanovic, Maša Alečković, Callahan M Wilde, Renee C Geck, Shaokun Shu, Natalie L Kingston, Nicholas W Harper, Vanessa Almendro, Alanna L Pyke, Shawn B Egri, Malvina Papanastasiou, M Kendell Clement, Ningxuan Zhou, Sarah R Walker, Jacqueline Salas, So Yeon Park, David A Frank, Alexander Meissner, Jacob D Jaffe, Piotr Sicinski, Alex Toker, Franziska Michor, Henry W Long, Beth A Overmoyer, Kornelia Polyak
JAK-STAT signaling in inflammatory breast cancer enables chemotherapy-resistant cell states. Cancer research (2022)
Tanya E Keenan, Tianyu Li, Tuulia Vallius, Jennifer L Guerriero, Nabihah Tayob, Bose Kochupurakkal, Janae A Davis, Ricardo Pastorello, Rie K Tahara, Leilani Anderson, Jake Conway, Meng X He, Erin Shannon, Robert E Godin, Peter Karl Sorger, Alan D' Andrea, Beth A Overmoyer, Eric P Winer, Elizabeth A Mittendorf, Eliezer M Van Allen, Geoffrey I Shapiro, Sara M Tolaney
Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (4) (2020)
Huma Q Rana, Rosalba Sacca, Christine Drogan, Stephanie Gutierrez, Emily Schlosnagle, Meredith M Regan, Virginia Speare, Holly LaDuca, Jill Dolinsky, Judy E Garber, Beth A Overmoyer
Prevalence of germline variants in inflammatory breast cancer. Cancer 125 (13) (2019)